After a Deal with Gilead, Galapagos is Still Doing Phase II Trials with AbbVie

17/02/2016 - 3 minutes

Galapagos (Belgium) is moving forward with their cystic fibrosis drug candidate after promising Phase I results – and still in collaboration with AbbVie (US). Curiouser and curiouser…

galapagos_abbvie_cystic_fibrosisGalapagos is one of the most hotly-discussed Biotechs in Europe, with around 400 employees and historic IPOs on NASDAQ. It is partnered with several big Pharma, like Gilead, AbbVie, Servier (to develop therapies for osteoarthritis) and MorphoSys (in inflammatory diseases).

However, it has not always been smooth sailing – Galapagos was left high and dry by GSK in 2014 and most infamously by AbbVie in late 2015.

AbbVie pulled out of a collaboration for a rheumatoid drug (filgotinib) despite good Phase II results – arguably a counterintuitive move.

The pharma company which filled the vacant spot turned out to be Gilead (US). It agreed to collaborate in the Phase III trial of filgotinib, and also acquired almost 15% of Galapagos –

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!